<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624867</url>
  </required_header>
  <id_info>
    <org_study_id>HP-1050-US-02</org_study_id>
    <nct_id>NCT04624867</nct_id>
  </id_info>
  <brief_title>Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch</brief_title>
  <official_title>A Phase I Study to Assess Skin Irritation and Sensitization of HP-1050 Transdermal System Compared to XULANE in Healthy Adult Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, evaluator-blinded study to assess skin irritation and skin sensitization of&#xD;
      HP-1050 transdermal system (HP-1050) in comparison to XULANE patch in healthy female&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dual-center, evaluator-blinded, randomized phase 1 study evaluating skin irritation&#xD;
      and skin sensitization of HP-1050 transdermal system in comparison to XULANE patch in healthy&#xD;
      female volunteers. The study will consist of a 4-week Screening Phase and a Treatment Phase.&#xD;
      The Treatment Phase will consist of the following periods: an Induction Period, a Rest Period&#xD;
      followed by a Challenge Period and if needed, a Re-Challenge Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Irritation Evaluation</measure>
    <time_frame>21 days</time_frame>
    <description>To evaluate skin irritation after exposure to HP-1050 compared to XULANE®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitization Evaluation</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate skin sensitization after exposure to HP-1050 compared to XULANE®</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cumulative Irritation and Sensitization</condition>
  <arm_group>
    <arm_group_label>HP-1050 patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP-1050 and Xulane will be administered simultaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP-1050 Patch</intervention_name>
    <description>Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.</description>
    <arm_group_label>HP-1050 patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy non-pregnant, non-lactating females 18-35 years of age (inclusive0 and who are&#xD;
             candidates for hormonal contraception;&#xD;
&#xD;
          -  Subjects who have previously used hormonal contraceptives without complications or&#xD;
             naïve subjects for whom hormonal contraceptives are not contraindicated in the opinion&#xD;
             of the Principal Investigator;&#xD;
&#xD;
          -  Subjects who are willing to stop using any current contraceptives for the duration of&#xD;
             the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are currently taking or have taken oral hormonal contraceptives within 30&#xD;
             days prior to the first patch application;&#xD;
&#xD;
          -  Subjects who are currently using any long-acting hormonal method of contraception or&#xD;
             has used them within the past 3 months;&#xD;
&#xD;
          -  Subjects who have a contraindication for estrogen or norelgestromin, or subjects who&#xD;
             have a history of sensitivity to estrogen or norelgestromin or any related&#xD;
             derivatives;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>305 253 5099</phone>
    <email>ClinicalTrials@noven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>QPS Missouri</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

